Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Post by stargazer1on Jan 10, 2024 2:32pm
293 Views
Post# 35819932

Next press release should be good. LowMoor, a question

Next press release should be good. LowMoor, a questionFrom the press releases that have been released, all results are positive. The next press release will probably be an update on how the trials are progressing. If it is better than expected, the stock could edge up some. As the patient trials progress and continue to show positive results, the price rise will accellerate.

LowMoor I have a question. I have been trying to find a site that shows NGENF insider trades. Every site that I have found says that they have no informatio on insider trading.

Where did you find your information? Is it your brokerage site? Or a site where you have to pay? I am willing to pay for a site.

Thanks.

I am holding NGENF for the long haul. If they can cause damaged neurons to recover, or new ones to replace them, this could go to several hundred dollars a share, or even be one of the $1,000 stocks. Although long before that, it would probably be bought by one of the giant pharm companies. But, even so, they would pay big bucks to acquire our company.
<< Previous
Bullboard Posts
Next >>